The current landscape of immunotherapy for pediatric brain tumors.
Journal
Nature cancer
ISSN: 2662-1347
Titre abrégé: Nat Cancer
Pays: England
ID NLM: 101761119
Informations de publication
Date de publication:
01 2022
01 2022
Historique:
received:
08
10
2020
accepted:
24
11
2021
entrez:
5
2
2022
pubmed:
6
2
2022
medline:
20
4
2022
Statut:
ppublish
Résumé
Pediatric central nervous system tumors are the most common solid malignancies in childhood, and aggressive therapy often leads to long-term sequelae in survivors, making these tumors challenging to treat. Immunotherapy has revolutionized prospects for many cancer types in adults, but the intrinsic complexity of treating pediatric patients and the scarcity of clinical studies of children to inform effective approaches have hampered the development of effective immunotherapies in pediatric settings. Here, we review recent advances and ongoing challenges in pediatric brain cancer immunotherapy, as well as considerations for efficient clinical translation of efficacious immunotherapies into pediatric settings.
Identifiants
pubmed: 35121998
doi: 10.1038/s43018-021-00319-0
pii: 10.1038/s43018-021-00319-0
doi:
Substances chimiques
Immunologic Factors
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
11-24Informations de copyright
© 2022. Springer Nature America, Inc.
Références
Pollack, I. F. Brain tumors in children. N. Engl. J. Med. 331, 1500–1507 (1994).
pubmed: 7969301
doi: 10.1056/NEJM199412013312207
Cohen, K. J. et al. Temozolomide in the treatment of children with newly diagnosed diffuse intrinsic pontine gliomas: a report from the Children’s Oncology Group. Neuro Oncol. 13, 410–416 (2011).
pubmed: 21345842
pmcid: 3064697
doi: 10.1093/neuonc/noq205
Chan, T. A., Wolchok, J. D. & Snyder, A. Genetic basis for clinical response to CTLA-4 blockade in melanoma. N. Engl. J. Med. 373, 1984 (2015).
pubmed: 26559592
doi: 10.1056/NEJMc1508163
Hamid, O. et al. Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma. N. Engl. J. Med. 369, 134–144 (2013).
pubmed: 23724846
pmcid: 4126516
doi: 10.1056/NEJMoa1305133
Okada, H. et al. Immunotherapeutic approaches for glioma. Crit. Rev. Immunol. 29, 1–42 (2009).
pubmed: 19348609
pmcid: 2713019
doi: 10.1615/CritRevImmunol.v29.i1.10
Walker, P. R., Calzascia, T., de Tribolet, N. & Dietrich, P. Y. T-cell immune responses in the brain and their relevance for cerebral malignancies. Brain Res. Brain Res. Rev. 42, 97–122 (2003).
pubmed: 12738053
doi: 10.1016/S0165-0173(03)00141-3
Platten, M. & Reardon, D. A. Concepts for immunotherapies in gliomas. Semin. Neurol. 38, 62–72 (2018).
Engelhardt, B. Molecular mechanisms involved in T cell migration across the blood–brain barrier. J. Neural Transm. 113, 477–485 (2006).
pubmed: 16550326
doi: 10.1007/s00702-005-0409-y
Krakowski, M. L. & Owens, T. The central nervous system environment controls effector CD4
pubmed: 9394808
doi: 10.1002/eji.1830271115
Albert, M. L. et al. Tumor-specific killer cells in paraneoplastic cerebellar degeneration. Nat. Med. 4, 1321–1324 (1998).
pubmed: 9809559
doi: 10.1038/3315
Okada, H. & Pollack, I. F. Cytokine gene therapy for malignant glioma. Expert Opin. Biol. Ther. 4, 1609–1620 (2004).
pubmed: 15461572
doi: 10.1517/14712598.4.10.1609
Okada, H. et al. Gene therapy of malignant gliomas: a pilot study of vaccination with irradiated autologous glioma and dendritic cells admixed with IL-4 transduced fibroblasts to elicit an immune response. Hum. Gene Ther. 12, 575–595 (2001).
pubmed: 11268289
doi: 10.1089/104303401300042528
Okada, H. et al. Autologous glioma cell vaccine admixed with interleukin-4 gene transfected fibroblasts in the treatment of patients with malignant gliomas. J. Transl. Med. 5, 67 (2007).
pubmed: 18093335
pmcid: 2254376
doi: 10.1186/1479-5876-5-67
Liau, L. M. et al. Dendritic cell vaccination in glioblastoma patients induces systemic and intracranial T-cell responses modulated by the local central nervous system tumor microenvironment. Clin. Cancer Res. 11, 5515–5525 (2005).
pubmed: 16061868
doi: 10.1158/1078-0432.CCR-05-0464
Wheeler, C. J. et al. Vaccination elicits correlated immune and clinical responses in glioblastoma multiforme patients. Cancer Res. 68, 5955–5964 (2008).
pubmed: 18632651
doi: 10.1158/0008-5472.CAN-07-5973
Yamanaka, R. et al. Clinical evaluation of dendritic cell vaccination for patients with recurrent glioma: results of a clinical phase I/II trial. Clin. Cancer Res. 11, 4160–4167 (2005).
pubmed: 15930352
doi: 10.1158/1078-0432.CCR-05-0120
Yu, J. S. et al. Vaccination with tumor lysate-pulsed dendritic cells elicits antigen-specific, cytotoxic T-cells in patients with malignant glioma. Cancer Res. 64, 4973–4979 (2004).
pubmed: 15256471
doi: 10.1158/0008-5472.CAN-03-3505
Liau, L. M. et al. First results on survival from a large phase 3 clinical trial of an autologous dendritic cell vaccine in newly diagnosed glioblastoma. J. Transl. Med. 16, 142 (2018).
pubmed: 29843811
pmcid: 5975654
doi: 10.1186/s12967-018-1507-6
Dutoit, V. et al. Antigenic expression and spontaneous immune responses support the use of a selected peptide set from the IMA950 glioblastoma vaccine for immunotherapy of grade II and III glioma. Oncoimmunology 7, e1391972 (2018).
pubmed: 29308320
doi: 10.1080/2162402X.2017.1391972
Okada, H. et al. Induction of CD8
pubmed: 21149657
doi: 10.1200/JCO.2010.30.7744
Weller, M. et al. Rindopepimut with temozolomide for patients with newly diagnosed, EGFR
pubmed: 28844499
doi: 10.1016/S1470-2045(17)30517-X
Hilf, N. et al. Actively personalized vaccination trial for newly diagnosed glioblastoma. Nature 565, 240–245 (2019).
pubmed: 30568303
doi: 10.1038/s41586-018-0810-y
Tocagen. Tocagen Reports Results of Toca 5 Phase 3 Trial in Recurrent Brain Cancer http://ir.tocagen.com/news-releases/news-release-details/tocagen-reports-results-toca-5-phase-3-trial-recurrent-brain (2019).
Filley, A. C., Henriquez, M. & Dey, M. Recurrent glioma clinical trial, CheckMate-143: the game is not over yet. Oncotarget 8, 91779–91794 (2017).
pubmed: 29207684
pmcid: 5710964
doi: 10.18632/oncotarget.21586
Bristol Myers Squibb. Bristol-Myers Squibb Announces Phase 3 CheckMate -498 Study Did Not Meet Primary Endpoint of Overall Survival with Opdivo (Nivolumab) Plus Radiation in Patients with Newly Diagnosed MGMT-Unmethylated Glioblastoma Multiforme https://news.bms.com/press-release/corporatefinancial-news/bristol-myers-squibb-announces-phase-3-checkmate-498-study-did (2019).
Bristol Myers Squibb. Bristol-Myers Squibb Provides Update on Phase 3 Opdivo (Nivolumab) CheckMate -548 Trial in Patients with Newly Diagnosed MGMT-Methylated Glioblastoma Multiforme https://news.bms.com/press-release/corporatefinancial-news/bristol-myers-squibb-provides-update-phase-3-opdivo-nivolumab- (2019).
Brown, C. E. et al. Regression of glioblastoma after chimeric antigen receptor T-cell therapy. N. Engl. J. Med. 375, 2561–2569 (2016).
pubmed: 28029927
pmcid: 5390684
doi: 10.1056/NEJMoa1610497
Louis, D. N. et al. The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary. Acta Neuropathol. 131, 803–820 (2016).
pubmed: 27157931
doi: 10.1007/s00401-016-1545-1
Sturm, D. et al. Paediatric and adult glioblastoma: multiform (epi)genomic culprits emerge. Nat. Rev. Cancer 14, 92–107 (2014).
pubmed: 24457416
pmcid: 4003223
doi: 10.1038/nrc3655
Watanabe, K. et al. Incidence and timing of p53 mutations during astrocytoma progression in patients with multiple biopsies. Clin. Cancer Res. 3, 523–530 (1997).
pubmed: 9815715
Reilly, K. M., Loisel, D. A., Bronson, R. T., McLaughlin, M. E. & Jacks, T. Nf1;Trp53 mutant mice develop glioblastoma with evidence of strain-specific effects. Nat. Genet. 26, 109–113 (2000).
pubmed: 10973261
doi: 10.1038/79075
Mackay, A. et al. Integrated molecular meta-analysis of 1,000 pediatric high-grade and diffuse intrinsic pontine glioma. Cancer Cell 32, 520–537 (2017).
pubmed: 28966033
pmcid: 5637314
doi: 10.1016/j.ccell.2017.08.017
Schwartzentruber, J. et al. Driver mutations in histone H3.3 and chromatin remodelling genes in paediatric glioblastoma. Nature 482, 226–231 (2012).
pubmed: 22286061
doi: 10.1038/nature10833
Guerreiro Stucklin, A. S. et al. Alterations in ALK/ROS1/NTRK/MET drive a group of infantile hemispheric gliomas. Nat. Commun. 10, 4343 (2019).
pubmed: 31554817
pmcid: 6761184
doi: 10.1038/s41467-019-12187-5
Chheda, Z. S. et al. Novel and shared neoantigen derived from histone 3 variant H3.3K27M mutation for glioma T cell therapy. J. Exp. Med. 215, 141–157 (2018).
pubmed: 29203539
pmcid: 5748856
doi: 10.1084/jem.20171046
Alexandrov, L. B. et al. Signatures of mutational processes in human cancer. Nature 500, 415–421 (2013).
pubmed: 23945592
pmcid: 3776390
doi: 10.1038/nature12477
Sonabend, A. M. et al. Medulloblasoma: challenges for effective immunotherapy. J. Neurooncol. 108, 1–10 (2012).
pubmed: 22173741
doi: 10.1007/s11060-011-0776-1
Rutledge, W. C. et al. Tumor-infiltrating lymphocytes in glioblastoma are associated with specific genomic alterations and related to transcriptional class. Clin. Cancer Res. 19, 4951–4960 (2013).
pubmed: 23864165
doi: 10.1158/1078-0432.CCR-13-0551
Krishnadas, D. K., Bai, F. & Lucas, K. G. Targeting cancer-testis antigens in recurrent pediatric brain tumors. J. Neurooncol. 123, 193–195 (2015).
pubmed: 25855497
doi: 10.1007/s11060-015-1765-6
Snyder, A. et al. Genetic basis for clinical response to CTLA-4 blockade in melanoma. N. Engl. J. Med. 371, 2189–2199 (2014).
pubmed: 25409260
pmcid: 4315319
doi: 10.1056/NEJMoa1406498
Wainwright, D. A. et al. IDO expression in brain tumors increases the recruitment of regulatory T cells and negatively impacts survival. Clin. Cancer Res. 18, 6110–6121 (2012).
pubmed: 22932670
pmcid: 3500434
doi: 10.1158/1078-0432.CCR-12-2130
Ke, X. et al. Roles of CD4
pubmed: 18508492
Lohr, J. et al. Effector T-cell infiltration positively impacts survival of glioblastoma patients and is impaired by tumor-derived TGF-β. Clin. Cancer Res. 17, 4296–4308 (2011).
pubmed: 21478334
doi: 10.1158/1078-0432.CCR-10-2557
Duraiswamy, J., Kaluza, K. M., Freeman, G. J. & Coukos, G. Dual blockade of PD-1 and CTLA-4 combined with tumor vaccine effectively restores T-cell rejection function in tumors. Cancer Res. 73, 3591–3603 (2013).
pubmed: 23633484
pmcid: 3686913
doi: 10.1158/0008-5472.CAN-12-4100
Kodumudi, K. N., Weber, A., Sarnaik, A. A. & Pilon-Thomas, S. Blockade of myeloid-derived suppressor cells after induction of lymphopenia improves adoptive T cell therapy in a murine model of melanoma. J. Immunol. 189, 5147–5154 (2012).
pubmed: 23100512
doi: 10.4049/jimmunol.1200274
Margol, A. et al. Tumor associated macrophages in SHH subgroup of medulloblastomas. Clin. Cancer Res. 21, 1457–1465 (2014).
Askew, K. et al. Coupled proliferation and apoptosis maintain the rapid turnover of microglia in the adult brain. Cell Rep. 18, 391–405 (2017).
pubmed: 28076784
pmcid: 5263237
doi: 10.1016/j.celrep.2016.12.041
Heimberger, A. B. et al. Incidence and prognostic impact of FoxP3
pubmed: 18698034
doi: 10.1158/1078-0432.CCR-08-0320
Bouffet, E. et al. Immune checkpoint inhibition for hypermutant glioblastoma multiforme resulting from germline biallelic mismatch repair deficiency. J. Clin. Oncol. 34, 2206–2211 (2016).
pubmed: 27001570
doi: 10.1200/JCO.2016.66.6552
Schlager, C. et al. Effector T-cell trafficking between the leptomeninges and the cerebrospinal fluid. Nature 530, 349–353 (2016).
pubmed: 26863192
doi: 10.1038/nature16939
Beatty, G. L. & Moon, E. K. Chimeric antigen receptor T cells are vulnerable to immunosuppressive mechanisms present within the tumor microenvironment. Oncoimmunology 3, e970027 (2014).
pubmed: 25941599
pmcid: 4292547
doi: 10.4161/21624011.2014.970027
van der Burg, S. H., Arens, R., Ossendorp, F., van Hall, T. & Melief, C. J. Vaccines for established cancer: overcoming the challenges posed by immune evasion. Nat. Rev. Cancer 16, 219–233 (2016).
pubmed: 26965076
doi: 10.1038/nrc.2016.16
Ochs, K. et al. K27M-mutant histone-3 as a novel target for glioma immunotherapy. Oncoimmunology. 6, e1328340 (2017).
pubmed: 28811969
pmcid: 5543817
doi: 10.1080/2162402X.2017.1328340
Gattinoni, L. et al. Removal of homeostatic cytokine sinks by lymphodepletion enhances the efficacy of adoptively transferred tumor-specific CD8
pubmed: 16203864
pmcid: 1397916
doi: 10.1084/jem.20050732
Suryadevara, C. M. et al. Temozolomide lymphodepletion enhances CAR abundance and correlates with antitumor efficacy against established glioblastoma. Oncoimmunology 7, e1434464 (2018).
pubmed: 29872570
pmcid: 5980382
doi: 10.1080/2162402X.2018.1434464
Desjardins, A. et al. Recurrent glioblastoma treated with recombinant poliovirus. N. Engl. J. Med. 379, 150–161 (2018).
pubmed: 29943666
pmcid: 6065102
doi: 10.1056/NEJMoa1716435
Fried, I. et al. Preliminary results of immune modulating antibody MDV9300 (pidilizumab) treatment in children with diffuse intrinsic pontine glioma. J. Neurooncol. 136, 189–195 (2018).
pubmed: 29143272
doi: 10.1007/s11060-017-2643-1
Geoerger, B. Anti-PD-1 shows promise against advanced paediatric Hodgkin lymphoma—author’s reply. Lancet Oncol. 21, e127 (2020).
pubmed: 32135111
doi: 10.1016/S1470-2045(20)30105-4
Kostine, M. et al. Baseline co-medications may alter the anti-tumoural effect of checkpoint inhibitors as well as the risk of immune-related adverse events. Eur. J. Cancer 157, 474–484 (2021).
pubmed: 34649118
doi: 10.1016/j.ejca.2021.08.036
Grabovska, Y. et al. Pediatric pan-central nervous system tumor analysis of immune-cell infiltration identifies correlates of antitumor immunity. Nat. Commun. 11, 4324 (2020).
pubmed: 32859926
pmcid: 7455736
doi: 10.1038/s41467-020-18070-y
Cloughesy, T. F. et al. Neoadjuvant anti-PD-1 immunotherapy promotes a survival benefit with intratumoral and systemic immune responses in recurrent glioblastoma. Nat. Med. 25, 477–486 (2019).
pubmed: 30742122
pmcid: 6408961
doi: 10.1038/s41591-018-0337-7
Gholamin, S. et al. Disrupting the CD47–SIRPα anti-phagocytic axis by a humanized anti-CD47 antibody is an efficacious treatment for malignant pediatric brain tumors. Sci. Transl. Med. 9, eaaf2968 (2017).
Choi, B. D. et al. Systemic administration of a bispecific antibody targeting EGFR
pubmed: 23248284
doi: 10.1073/pnas.1219817110
Choi, B. D. et al. CAR-T cells secreting BiTEs circumvent antigen escape without detectable toxicity. Nat. Biotechnol. 37, 1049–1058 (2019).
pubmed: 31332324
doi: 10.1038/s41587-019-0192-1
Heiss, J. D. et al. Phase I trial of convection-enhanced delivery of IL13–Pseudomonas toxin in children with diffuse intrinsic pontine glioma. J. Neurosurg. Pediatr. 23, 333–342 (2018).
pubmed: 30544335
pmcid: 7266009
doi: 10.3171/2018.9.PEDS17225
Souweidane, M. M. et al. Convection-enhanced delivery for diffuse intrinsic pontine glioma: a single-centre, dose-escalation, phase 1 trial. Lancet Oncol. 19, 1040–1050 (2018).
pubmed: 29914796
pmcid: 6692905
doi: 10.1016/S1470-2045(18)30322-X
Yerrabelli, R. S. et al. IntraOmmaya compartmental radioimmunotherapy using
pubmed: 33047248
doi: 10.1007/s00259-020-05050-z
He, P. et al. Two-compartment model of radioimmunotherapy delivered through cerebrospinal fluid. Eur. J. Nucl. Med. Mol. Imaging 38, 334–342 (2011).
pubmed: 20936407
doi: 10.1007/s00259-010-1633-8
Lee, D. W. et al. T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial. Lancet 385, 517–528 (2015).
pubmed: 25319501
doi: 10.1016/S0140-6736(14)61403-3
Hong, J. J. et al. Successful treatment of melanoma brain metastases with adoptive cell therapy. Clin. Cancer Res. 16, 4892–4898 (2010).
pubmed: 20719934
pmcid: 6291850
doi: 10.1158/1078-0432.CCR-10-1507
Goff, S. L. et al. Pilot trial of adoptive transfer of chimeric antigen receptor-transduced T cells targeting EGFR
pubmed: 30882547
pmcid: 6691897
doi: 10.1097/CJI.0000000000000260
Ahmed, N. et al. HER2-specific chimeric antigen receptor-modified virus-specific T cells for progressive glioblastoma: a phase 1 dose-escalation trial. JAMA Oncol. 3, 1094–1101 (2017).
pubmed: 28426845
pmcid: 5747970
doi: 10.1001/jamaoncol.2017.0184
Akhavan, D. et al. CAR T cells for brain tumors: lessons learned and road ahead. Immunol. Rev. 290, 60–84 (2019).
pubmed: 31355493
pmcid: 6771592
doi: 10.1111/imr.12773
O’Rourke, D. M. et al. A single dose of peripherally infused EGFR
Mount, C. W. et al. Potent antitumor efficacy of anti-GD2 CAR T cells in H3-K27M. Nat. Med. 24, 572–579 (2018).
pubmed: 29662203
pmcid: 6214371
doi: 10.1038/s41591-018-0006-x
Maude, S. L. et al. Chimeric antigen receptor T cells for sustained remissions in leukemia. N. Engl. J. Med. 371, 1507–1517 (2014).
pubmed: 25317870
pmcid: 4267531
doi: 10.1056/NEJMoa1407222
Majzner, R. G. et al. CAR T cells targeting B7-H3, a pan-cancer antigen, demonstrate potent preclinical activity against pediatric solid tumors and brain tumors. Clin. Cancer Res. 25, 2560–2574 (2019).
pubmed: 30655315
pmcid: 8456711
doi: 10.1158/1078-0432.CCR-18-0432
Long, A. H. et al. 4-1BB costimulation ameliorates T cell exhaustion induced by tonic signaling of chimeric antigen receptors. Nat. Med. 21, 581–590 (2015).
pubmed: 25939063
pmcid: 4458184
doi: 10.1038/nm.3838
Patterson, J. D., Henson, J. C., Breese, R. O., Bielamowicz, K. J. & Rodriguez, A. CAR T cell therapy for pediatric brain tumors. Front. Oncol. 10, 1582 (2020).
pubmed: 32903405
pmcid: 7435009
doi: 10.3389/fonc.2020.01582
Hanahan, D. & Weinberg, R. A. Hallmarks of cancer: the next generation. Cell 144, 646–674 (2011).
pubmed: 21376230
doi: 10.1016/j.cell.2011.02.013
Khuong-Quang, D. A. et al. K27M mutation in histone H3.3 defines clinically and biologically distinct subgroups of pediatric diffuse intrinsic pontine gliomas. Acta Neuropathol. 124, 439–447 (2012).
pubmed: 22661320
pmcid: 3422615
doi: 10.1007/s00401-012-0998-0
Mueller, S. et al. Mass cytometry detects H3.3K27M-specific vaccine responses in diffuse midline glioma. J. Clin. Invest. 130, 6325–6337 (2020).
pubmed: 32817593
pmcid: 7685729
doi: 10.1172/JCI140378
Pollack, I. F. et al. Antigen-specific immune responses and clinical outcome after vaccination with glioma-associated antigen peptides and polyinosinic–polycytidylic acid stabilized by lysine and carboxymethylcellulose in children with newly diagnosed malignant brainstem and nonbrainstem gliomas. J. Clin. Oncol. 32, 2050–2058 (2014).
pubmed: 24888813
pmcid: 4067943
doi: 10.1200/JCO.2013.54.0526
Pollack, I. F. et al. Antigen-specific immunoreactivity and clinical outcome following vaccination with glioma-associated antigen peptides in children with recurrent high-grade gliomas: results of a pilot study. J. Neurooncol. 130, 517–527 (2016).
pubmed: 27624914
pmcid: 5363717
doi: 10.1007/s11060-016-2245-3
Ahluwalia, M. et al. SurVaxM with standard therapy in newly diagnosed glioblastoma: phase II trial update. J. Clin. Oncol. 37, 15_suppl (2016).
Fenstermaker, R. A. et al. Clinical study of a survivin long peptide vaccine (SurVaxM) in patients with recurrent malignant glioma. Cancer Immunol. Immunother. 65, 1339–1352 (2016).
pubmed: 27576783
pmcid: 5069322
doi: 10.1007/s00262-016-1890-x
Flores, C. et al. Massive clonal expansion of medulloblastoma-specific T cells during adoptive cellular therapy. Sci. Adv. 5, eaav9879 (2019).
pubmed: 31807694
pmcid: 6881165
doi: 10.1126/sciadv.aav9879
Aurelian, L. Oncolytic viruses as immunotherapy: progress and remaining challenges. Onco Targets Ther. 9, 2627–2637 (2016).
pubmed: 27226725
pmcid: 4863691
doi: 10.2147/OTT.S63049
Regina, A. et al. ANG4043, a novel brain-penetrant peptide–mAb conjugate, is efficacious against HER2-positive intracranial tumors in mice. Mol. Cancer Ther. 14, 129–140 (2015).
pubmed: 25492620
doi: 10.1158/1535-7163.MCT-14-0399
Haanen, J. B. A. G. et al. Management of toxicities from immunotherapy: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann. Oncol. 29, iv264–iv266 (2018).
pubmed: 29917046
doi: 10.1093/annonc/mdy162
Brahmer, J. R., Lacchetti, C. & Thompson, J. A. Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: American Society of Clinical Oncology clinical practice guideline summary. J. Oncol. Pract. 14, 247–249 (2018).
pubmed: 29517954
doi: 10.1200/JOP.18.00005
Thompson, J. A. New NCCN Guidelines: Recognition and Management of Immunotherapy-Related Toxicity. J. Natl Compr. Canc. Netw. 16, 594–596 (2018).
pubmed: 29784734
doi: 10.6004/jnccn.2018.0047
Puzanov, I. et al. Managing toxicities associated with immune checkpoint inhibitors: consensus recommendations from the Society for Immunotherapy of Cancer (SITC) Toxicity Management Working Group. J. Immunother. Cancer 5, 95 (2017).
pubmed: 29162153
pmcid: 5697162
doi: 10.1186/s40425-017-0300-z
Johnson, D. B. et al. Fulminant myocarditis with combination immune checkpoint blockade. N. Engl. J. Med. 375, 1749–1755 (2016).
pubmed: 27806233
pmcid: 5247797
doi: 10.1056/NEJMoa1609214
Johnson, D. B. & Balko, J. M. Biomarkers for immunotherapy toxicity: are cytokines the answer? Clin. Cancer Res. 25, 1452–1454 (2019).
pubmed: 30587548
doi: 10.1158/1078-0432.CCR-18-3858
Johnson, D. B. et al. Neurologic toxicity associated with immune checkpoint inhibitors: a pharmacovigilance study. J. Immunother. Cancer 7, 134 (2019).
pubmed: 31118078
pmcid: 6530194
doi: 10.1186/s40425-019-0617-x
Johnson, D. B. et al. Immune checkpoint inhibitor toxicities: systems-based approaches to improve patient care and research. Lancet Oncol. 21, e398–e404 (2020).
pubmed: 32758477
doi: 10.1016/S1470-2045(20)30107-8
Kennedy, L. B. & Salama, A. K. S. A review of immune-mediated adverse events in melanoma. Oncol. Ther. 7, 101–120 (2019).
pubmed: 32699983
pmcid: 7359990
doi: 10.1007/s40487-019-0096-8
Weber, J. S. et al. Safety profile of nivolumab monotherapy: a pooled analysis of patients with advanced melanoma. J. Clin. Oncol. 35, 785–792 (2017).
pubmed: 28068177
doi: 10.1200/JCO.2015.66.1389
Roth, P. et al. Neurological complications of cancer immunotherapy. Cancer Treat. Rev. 97, 102189 (2021).
pubmed: 33872978
doi: 10.1016/j.ctrv.2021.102189
Morgan, R. A. et al. Cancer regression and neurological toxicity following anti-MAGE-A3 TCR gene therapy. J. Immunother. 36, 133–151 (2013).
pubmed: 23377668
pmcid: 3581823
doi: 10.1097/CJI.0b013e3182829903
Acharya, U. H. et al. Management of cytokine release syndrome and neurotoxicity in chimeric antigen receptor (CAR) T cell therapy. Expert Rev. Hematol. 12, 195–205 (2019).
pubmed: 30793644
doi: 10.1080/17474086.2019.1585238
Gust, J. et al. Endothelial activation and blood–brain barrier disruption in neurotoxicity after adoptive immunotherapy with CD19 CAR-T cells. Cancer Discov. 7, 1404–1419 (2017).
pubmed: 29025771
pmcid: 5718945
doi: 10.1158/2159-8290.CD-17-0698
Locke, F. L. et al. Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1–2 trial. Lancet Oncol. 20, 31–42 (2019).
pubmed: 30518502
doi: 10.1016/S1470-2045(18)30864-7
Schuster, S. J. et al. Tisagenlecleucel in adult relapsed or refractory diffuse large B-cell lymphoma. N. Engl. J. Med. 380, 45–56 (2019).
pubmed: 30501490
doi: 10.1056/NEJMoa1804980
Postow, M. A., Sidlow, R. & Hellmann, M. D. Immune-related adverse events associated with immune checkpoint blockade. N. Engl. J. Med. 378, 158–168 (2018).
pubmed: 29320654
doi: 10.1056/NEJMra1703481
Yu, L. et al. GD2-specific chimeric antigen receptor-modified T cells for the treatment of refractory and/or recurrent neuroblastoma in pediatric patients. J. Cancer Res. Clin. Oncol. https://doi.org/10.1007/s00432-021-03839-5 (2021).
Castel, D. et al. Histone H3F3A and HIST1H3B K27M mutations define two subgroups of diffuse intrinsic pontine gliomas with different prognosis and phenotypes. Acta Neuropathol. 130, 815–827 (2015).
pubmed: 26399631
pmcid: 4654747
doi: 10.1007/s00401-015-1478-0
Solomon, D. A. et al. Diffuse midline gliomas with histone H3-K27M mutation: a series of 47 cases assessing the spectrum of morphologic variation and associated genetic alterations. Brain Pathol. 26, 569–580 (2016).
pubmed: 26517431
doi: 10.1111/bpa.12336
Misuraca, K. L., Cordero, F. J. & Becher, O. J. Pre-clinical models of diffuse intrinsic pontine glioma. Front. Oncol. 5, 172 (2015).
pubmed: 26258075
pmcid: 4513210
doi: 10.3389/fonc.2015.00172
Dey, J. et al. A distinct Smoothened mutation causes severe cerebellar developmental defects and medulloblastoma in a novel transgenic mouse model. Mol. Cell. Biol. 32, 4104–4115 (2012).
pubmed: 22869526
pmcid: 3457348
doi: 10.1128/MCB.00862-12
Pei, Y. et al. An animal model of MYC-driven medulloblastoma. Cancer Cell 21, 155–167 (2012).
pubmed: 22340590
pmcid: 3285431
doi: 10.1016/j.ccr.2011.12.021
Huang, M. et al. Engineering genetic predisposition in human neuroepithelial stem cells recapitulates medulloblastoma tumorigenesis. Cell Stem Cell 25, 433–446 (2019).
pubmed: 31204176
pmcid: 6731167
doi: 10.1016/j.stem.2019.05.013
Cordero, F. J. et al. Histone H3.3K27M represses p16 to accelerate gliomagenesis in a murine model of DIPG. Mol. Cancer Res. 15, 1243–1254 (2017).
pubmed: 28522693
pmcid: 5581686
doi: 10.1158/1541-7786.MCR-16-0389
Ng, J. M. et al. Generation of a mouse model of atypical teratoid/rhabdoid tumor of the central nervous system through combined deletion of Snf5 and p53. Cancer Res. 75, 4629–4639 (2015).
pubmed: 26363008
pmcid: 4631617
doi: 10.1158/0008-5472.CAN-15-0874
Mestas, J. & Hughes, C. C. Of mice and not men: differences between mouse and human immunology. J. Immunol. 172, 2731–2738 (2004).
pubmed: 14978070
doi: 10.4049/jimmunol.172.5.2731
Piccioni, D. E. et al. Analysis of cell-free circulating tumor DNA in 419 patients with glioblastoma and other primary brain tumors. CNS Oncol. 8, CNS34 (2019).
Zhang, L., Li, Y., Meng, W., Ni, Y. & Gao, Y. Dynamic urinary proteomic analysis in a Walker 256 intracerebral tumor model. Cancer Med. 8, 3553–3565 (2019).
pubmed: 31090175
pmcid: 6601583
doi: 10.1002/cam4.2240
Elshafeey, N. et al. Multicenter study demonstrates radiomic features derived from magnetic resonance perfusion images identify pseudoprogression in glioblastoma. Nat. Commun. 10, 3170 (2019).
pubmed: 31320621
pmcid: 6639324
doi: 10.1038/s41467-019-11007-0
Schwalbe, E. C. et al. Novel molecular subgroups for clinical classification and outcome prediction in childhood medulloblastoma: a cohort study. Lancet Oncol. 18, 958–971 (2017).
pubmed: 28545823
pmcid: 5489698
doi: 10.1016/S1470-2045(17)30243-7
Kreiter, S. et al. Mutant MHC class II epitopes drive therapeutic immune responses to cancer. Nature 520, 692–696 (2015).
pubmed: 25901682
pmcid: 4838069
doi: 10.1038/nature14426
Pajtler, K. W. et al. The current consensus on the clinical management of intracranial ependymoma and its distinct molecular variants. Acta Neuropathol. 133, 5–12 (2017).
pubmed: 27858204
doi: 10.1007/s00401-016-1643-0
Buczkowicz, P. et al. Genomic analysis of diffuse intrinsic pontine gliomas identifies three molecular subgroups and recurrent activating ACVR1 mutations. Nat. Genet. 46, 451–456 (2014).
pubmed: 24705254
pmcid: 3997489
doi: 10.1038/ng.2936
Donson, A. M. et al. Immune gene and cell enrichment is associated with a good prognosis in ependymoma. J. Immunol. 183, 7428–7440 (2009).
pubmed: 19917695
doi: 10.4049/jimmunol.0902811
Doucette, T. et al. Immune heterogeneity of glioblastoma subtypes: extrapolation from the Cancer Genome Atlas. Cancer Immunol. Res. 1, 112–122 (2013).
pubmed: 24409449
doi: 10.1158/2326-6066.CIR-13-0028
Davis, A. A. & Patel, V. G. The role of PD-L1 expression as a predictive biomarker: an analysis of all US Food and Drug Administration (FDA) approvals of immune checkpoint inhibitors. J. Immunother. Cancer 7, 278 (2019).
pubmed: 31655605
pmcid: 6815032
doi: 10.1186/s40425-019-0768-9
Rozeman, E. A. & Blank, C. U. Combining checkpoint inhibition and targeted therapy in melanoma. Nat. Med. 25, 879–882 (2019).
pubmed: 31171877
doi: 10.1038/s41591-019-0482-7
Deng, J. et al. CDK4/6 inhibition augments antitumor immunity by enhancing T-cell activation. Cancer Discov. 8, 216–233 (2018).
pubmed: 29101163
doi: 10.1158/2159-8290.CD-17-0915
Franchimont, D. Overview of the actions of glucocorticoids on the immune response: a good model to characterize new pathways of immunosuppression for new treatment strategies. Ann. NY Acad. Sci. 1024, 124–137 (2004).
pubmed: 15265777
doi: 10.1196/annals.1321.009
Maxwell, R. et al. Contrasting impact of corticosteroids on anti-PD-1 immunotherapy efficacy for tumor histologies located within or outside the central nervous system. Oncoimmunology 7, e1500108 (2018).
pubmed: 30524891
pmcid: 6279341
doi: 10.1080/2162402X.2018.1500108
Pan, E. Y., Merl, M. Y. & Lin, K. The impact of corticosteroid use during anti-PD1 treatment. J. Oncol. Pharm. Pract. 26, 814–822 (2020).
Zhu, X. et al. Severe cerebral edema following nivolumab treatment for pediatric glioblastoma: case report. J. Neurosurg. Pediatr. 19, 249–253 (2017).
pubmed: 27858578
doi: 10.3171/2016.8.PEDS16326
Hwang, E. et al. Outcome of patients with recurrent diffuse intrinsic pontine glioma (DIPG) treated with pembrolizumab (anti-PD-1): a pediatric brain tumor consortium study (PBTC045). Neuro Oncol. 20, i100 (2018).
Okada, H. et al. Immunotherapy response assessment in neuro-oncology: a report of the RANO working group. Lancet Oncol. 16, e534–e542 (2015).
pubmed: 26545842
pmcid: 4638131
doi: 10.1016/S1470-2045(15)00088-1
Ceschin, R. et al. Parametric response mapping of apparent diffusion coefficient as an imaging biomarker to distinguish pseudoprogression from true tumor progression in peptide-based vaccine therapy for pediatric diffuse intrinsic pontine glioma. AJNR Am. J. Neuroradiol. 36, 2170–2176 (2015).
pubmed: 26338910
pmcid: 4644687
doi: 10.3174/ajnr.A4428
Bloch, O. et al. Gliomas promote immunosuppression through induction of B7-H1 expression in tumor-associated macrophages. Clin. Cancer Res. 19, 3165–3175 (2013).
pubmed: 23613317
pmcid: 3742575
doi: 10.1158/1078-0432.CCR-12-3314
Pham, C. D. et al. Differential immune microenvironments and response to immune checkpoint blockade among molecular subtypes of murine medulloblastoma. Clin. Cancer Res. 22, 582–595 (2016).
pubmed: 26405194
doi: 10.1158/1078-0432.CCR-15-0713
Nguyen, A. T. et al. Evidence for BRAF V600E and H3F3A K27M double mutations in paediatric glial and glioneuronal tumours. Neuropathol. Appl. Neurobiol. 41, 403–408 (2015).
pubmed: 25389051
doi: 10.1111/nan.12196
Duan, S. et al. PTEN deficiency reprogrammes human neural stem cells towards a glioblastoma stem cell-like phenotype. Nat. Commun. 6, 10068 (2015).
pubmed: 26632666
doi: 10.1038/ncomms10068
Bian, S. et al. Genetically engineered cerebral organoids model brain tumor formation. Nat. Methods 15, 631–639 (2018).
pubmed: 30038414
pmcid: 6071863
doi: 10.1038/s41592-018-0070-7
Ogawa, J., Pao, G. M., Shokhirev, M. N. & Verma, I. M. Glioblastoma model using human cerebral organoids. Cell Rep. 23, 1220–1229 (2018).
pubmed: 29694897
pmcid: 6892608
doi: 10.1016/j.celrep.2018.03.105
Koga, T. et al. Longitudinal assessment of tumor development using cancer avatars derived from genetically engineered pluripotent stem cells. Nat. Commun. 11, 550 (2020).
pubmed: 31992716
pmcid: 6987220
doi: 10.1038/s41467-020-14312-1
Monje, M. et al. Hedgehog-responsive candidate cell of origin for diffuse intrinsic pontine glioma. Proc. Natl Acad. Sci. USA 108, 4453–4458 (2011).
pubmed: 21368213
pmcid: 3060250
doi: 10.1073/pnas.1101657108
Hashizume, R. et al. Characterization of a diffuse intrinsic pontine glioma cell line: implications for future investigations and treatment. J. Neurooncol. 110, 305–313 (2012).
pubmed: 22983601
doi: 10.1007/s11060-012-0973-6
Harutyunyan, A. S. et al. H3K27M induces defective chromatin spread of PRC2-mediated repressive H3K27me2/me3 and is essential for glioma tumorigenesis. Nat. Commun. 10, 1262 (2019).
pubmed: 30890717
pmcid: 6425035
doi: 10.1038/s41467-019-09140-x
Chen, Z. et al. Advanced pediatric diffuse pontine glioma murine models pave the way towards precision medicine. Cancers 13, 1114 (2021).
pubmed: 33807733
pmcid: 7961799
doi: 10.3390/cancers13051114
Lan, X. et al. Modeling human pediatric and adult gliomas in immunocompetent mice through costimulatory blockade. Oncoimmunology 9, 1776577 (2020).
pubmed: 32923139
pmcid: 7458632
doi: 10.1080/2162402X.2020.1776577
Čančer, M. et al. Humanized stem cell models of pediatric medulloblastoma reveal an Oct4/mTOR axis that promotes malignancy. Cell Stem Cell 25, 855–870.e11 (2019).
pubmed: 31786016
pmcid: 6900751
doi: 10.1016/j.stem.2019.10.005
Badodi, S. et al. Convergence of BMI1 and CHD7 on ERK signaling in medulloblastoma. Cell Rep. 21, 2772–2784 (2017).
pubmed: 29212025
pmcid: 5732319
doi: 10.1016/j.celrep.2017.11.021
Shiraishi, R. & Kawauchi, D. Epigenetic regulation in medulloblastoma pathogenesis revealed by genetically engineered mouse models. Cancer Sci. 112, 2948–2957 (2021).
pubmed: 34050694
pmcid: 8353939
doi: 10.1111/cas.14990
Theruvath, J. et al. Locoregionally administered B7-H3-targeted CAR T cells for treatment of atypical teratoid/rhabdoid tumors. Nat. Med. 26, 712–719 (2020).
pubmed: 32341579
pmcid: 7992505
doi: 10.1038/s41591-020-0821-8
Terada, Y. et al. Human pluripotent stem cell-derived tumor model uncovers the embryonic stem cell signature as a key driver in atypical teratoid/rhabdoid tumor. Cell Rep. 26, 2608–2621.e6 (2019).
pubmed: 30840885
doi: 10.1016/j.celrep.2019.02.009
Smith, K. S. et al. Patient-derived orthotopic xenografts of pediatric brain tumors: a St. Jude resource. Acta Neuropathol. 140, 209–225 (2020).
pubmed: 32519082
pmcid: 7360541
doi: 10.1007/s00401-020-02171-5
Huq, S. et al. Preclinical efficacy of ribavirin in SHH and group 3 medulloblastoma. J. Neurosurg. Pediatr. 5, 1–7 (2021).
Andradas, C. et al. Assessment of cannabidiol and Δ9-tetrahydrocannabiol in mouse models of medulloblastoma and ependymoma. Cancers 13, 330 (2021).
pubmed: 33477420
pmcid: 7829707
doi: 10.3390/cancers13020330
Yu, L. et al. A clinically relevant orthotopic xenograft model of ependymoma that maintains the genomic signature of the primary tumor and preserves cancer stem cells in vivo. Neuro Oncol. 12, 580–594 (2010).
pubmed: 20511191
pmcid: 2940646
doi: 10.1093/neuonc/nop056
Haydar, D. et al. Cell-surface antigen profiling of pediatric brain tumors: B7-H3 is consistently expressed and can be targeted via local or systemic CAR T-cell delivery. Neuro Oncol. 23, 999–1011 (2021).
pubmed: 33320196
doi: 10.1093/neuonc/noaa278
Lenting, K., Verhaak, R., Ter Laan, M., Wesseling, P. & Leenders, W. Glioma: experimental models and reality. Acta Neuropathol. 133, 263–282 (2017).
Russell, W. L. et al. Specific-locus test shows ethylnitrosourea to be the most potent mutagen in the mouse. Proc. Natl Acad. Sci. USA 76, 5818–5819 (1979).
pubmed: 293686
pmcid: 411742
doi: 10.1073/pnas.76.11.5818
Mukherjee, J., Ghosh, A., Ghosh, A. & Chaudhuri, S. ENU administration causes genomic instability along with single nucleotide polymorphisms in p53 during gliomagenesis: T11TS administration demonstrated in vivo apoptosis of these genetically altered tumor cells. Cancer Biol. Ther. 5, 156–164 (2006).
pubmed: 16357521
doi: 10.4161/cbt.5.2.2313
Zook, B. C., Simmens, S. J. & Jones, R. V. Evaluation of ENU-induced gliomas in rats: nomenclature, immunochemistry, and malignancy. Toxicol. Pathol. 28, 193–201 (2000).
pubmed: 10669007
doi: 10.1177/019262330002800124
Koschmann, C. et al. Characterizing and targeting PDGFRA alterations in pediatric high-grade glioma. Oncotarget 7, 65696–65706 (2016).
pubmed: 27582545
pmcid: 5323185
doi: 10.18632/oncotarget.11602
Paugh, B. S. et al. Novel oncogenic PDGFRA mutations in pediatric high-grade gliomas. Cancer Res. 73, 6219–6229 (2013).
pubmed: 23970477
pmcid: 3800209
doi: 10.1158/0008-5472.CAN-13-1491
Puputti, M. et al. Amplification of KIT, PDGFRA, VEGFR2, and EGFR in gliomas. Mol. Cancer Res. 4, 927–934 (2006).
pubmed: 17189383
doi: 10.1158/1541-7786.MCR-06-0085
de Vries, N. A. et al. Rapid and robust transgenic high-grade glioma mouse models for therapy intervention studies. Clin. Cancer Res. 16, 3431–3441 (2010).
pubmed: 20472681
doi: 10.1158/1078-0432.CCR-09-3414
Holland, E. C. A mouse model for glioma: biology, pathology, and therapeutic opportunities. Toxicol. Pathol. 28, 171–177 (2000).
pubmed: 10669005
doi: 10.1177/019262330002800122
Bardella, C. et al. Expression of Idh1R132H in the murine subventricular zone stem cell niche recapitulates features of early gliomagenesis. Cancer Cell 30, 578–594 (2016).
pubmed: 27693047
pmcid: 5064912
doi: 10.1016/j.ccell.2016.08.017
Uhrbom, L., Hesselager, G., Nistér, M. & Westermark, B. Induction of brain tumors in mice using a recombinant platelet-derived growth factor B-chain retrovirus. Cancer Res. 58, 5275–5279 (1998).
pubmed: 9850047
Fisher, G. H. et al. Development of a flexible and specific gene delivery system for production of murine tumor models. Oncogene 18, 5253–5260 (1999).
pubmed: 10498877
doi: 10.1038/sj.onc.1203087
Hede, S. M. et al. GFAP promoter driven transgenic expression of PDGFB in the mouse brain leads to glioblastoma in a Trp53 null background. Glia 57, 1143–1153 (2009).
pubmed: 19115382
doi: 10.1002/glia.20837
Zhu, Y. et al. Early inactivation of p53 tumor suppressor gene cooperating with NF1 loss induces malignant astrocytoma. Cancer Cell 8, 119–130 (2005).
pubmed: 16098465
pmcid: 3024718
doi: 10.1016/j.ccr.2005.07.004
Kwon, C. H. et al. Pten haploinsufficiency accelerates formation of high-grade astrocytomas. Cancer Res. 68, 3286–3294 (2008).
pubmed: 18451155
pmcid: 2760841
doi: 10.1158/0008-5472.CAN-07-6867
Yu, K. et al. PIK3CA variants selectively initiate brain hyperactivity during gliomagenesis. Nature 578, 166–171 (2020).
pubmed: 31996845
pmcid: 7577741
doi: 10.1038/s41586-020-1952-2
Funato, K., Major, T., Lewis, P. W., Allis, C. D. & Tabar, V. Use of human embryonic stem cells to model pediatric gliomas with H3.3K27M histone mutation. Science 346, 1529–1533 (2014).
pubmed: 25525250
pmcid: 4995593
doi: 10.1126/science.1253799
Pathania, M. et al. H3.3K27M cooperates with Trp53 loss and PDGFRA gain in mouse embryonic neural progenitor cells to induce invasive high-grade gliomas. Cancer Cell 32, 684–700.e9 (2017).
pubmed: 29107533
pmcid: 5687892
doi: 10.1016/j.ccell.2017.09.014
Larson, J. D. et al. Histone H3.3 K27M accelerates spontaneous brainstem glioma and drives restricted changes in bivalent gene expression. Cancer Cell 35, 140–155.e7 (2019).
pubmed: 30595505
doi: 10.1016/j.ccell.2018.11.015
Becher, O. et al. Preclinical evaluation of radiation and perifosine in a genetically and histologically accurate model of brainstem glioma. Cancer Res. 70, 2548–2557 (2010).
pubmed: 20197468
doi: 10.1158/0008-5472.CAN-09-2503
Halvorson, K. G. et al. A high-throughput in vitro drug screen in a genetically engineered mouse model of diffuse intrinsic pontine glioma identifies BMS-754807 as a promising therapeutic agent. PLoS One 10, e0118926 (2015).
pubmed: 25748921
pmcid: 4352073
doi: 10.1371/journal.pone.0118926
Zuckermann, M. et al. Somatic CRISPR/Cas9-mediated tumour suppressor disruption enables versatile brain tumour modelling. Nat. Commun. 6, 7391 (2015).
pubmed: 26067104
doi: 10.1038/ncomms8391
Gibson, P. et al. Subtypes of medulloblastoma have distinct developmental origins. Nature 468, 1095–1099 (2010).
pubmed: 21150899
pmcid: 3059767
doi: 10.1038/nature09587
Robinson, G. et al. Novel mutations target distinct subgroups of medulloblastoma. Nature 488, 43–48 (2012).
pubmed: 22722829
pmcid: 3412905
doi: 10.1038/nature11213
Goodrich, L. V., Milenkovic, L., Higgins, K. M. & Scott, M. P. Altered neural cell fates and medulloblastoma in mouse patched mutants. Science 277, 1109–1113 (1997).
pubmed: 9262482
doi: 10.1126/science.277.5329.1109
Lee, Y. et al. Loss of suppressor-of-fused function promotes tumorigenesis. Oncogene 26, 6442–6447 (2007).
pubmed: 17452975
doi: 10.1038/sj.onc.1210467
Uziel, T. et al. The tumor suppressors Ink4c and p53 collaborate independently with patched to suppress medulloblastoma formation. Genes Dev. 19, 2656–2667 (2005).
pubmed: 16260494
pmcid: 1283959
doi: 10.1101/gad.1368605
Wetmore, C., Eberhart, D. E. & Curran, T. Loss of p53 but not ARF accelerates medulloblastoma in mice heterozygous for patched. Cancer Res. 61, 513–516 (2001).
pubmed: 11212243
Yang, Z. J. et al. Medulloblastoma can be initiated by deletion of patched in lineage-restricted progenitors or stem cells. Cancer Cell 14, 135–145 (2008).
pubmed: 18691548
pmcid: 2538687
doi: 10.1016/j.ccr.2008.07.003
Grammel, D. et al. Sonic hedgehog-associated medulloblastoma arising from the cochlear nuclei of the brainstem. Acta Neuropathol. 123, 601–614 (2012).
pubmed: 22349907
doi: 10.1007/s00401-012-0961-0
Forget, A. et al. Aberrant ERBB4-SRC signaling as a hallmark of group 4 medulloblastoma revealed by integrative phosphoproteomic profiling. Cancer Cell 34, 379–395.e7 (2018).
pubmed: 30205043
doi: 10.1016/j.ccell.2018.08.002
Hallahan, A. R. et al. The SmoA1 mouse model reveals that notch signaling is critical for the growth and survival of sonic hedgehog-induced medulloblastomas. Cancer Res. 64, 7794–7800 (2004).
pubmed: 15520185
doi: 10.1158/0008-5472.CAN-04-1813
Schüller, U. et al. Acquisition of granule neuron precursor identity is a critical determinant of progenitor cell competence to form Shh-induced medulloblastoma. Cancer Cell 14, 123–134 (2008).
pubmed: 18691547
pmcid: 2597270
doi: 10.1016/j.ccr.2008.07.005
Merk, D. J. et al. Opposing effects of CREBBP mutations govern the phenotype of Rubinstein-Taybi syndrome and adult SHH medulloblastoma. Dev. Cell 44, 709–724.e706 (2018).
pubmed: 29551561
doi: 10.1016/j.devcel.2018.02.012
Shi, X., Wang, Q., Gu, J., Xuan, Z. & Wu, J. I. SMARCA4/Brg1 coordinates genetic and epigenetic networks underlying Shh-type medulloblastoma development. Oncogene 35, 5746–5758 (2016).
pubmed: 27065321
doi: 10.1038/onc.2016.108
Hatton, B. A. et al. The Smo/Smo model: hedgehog-induced medulloblastoma with 90% incidence and leptomeningeal spread. Cancer Res. 68, 1768–1776 (2008).
pubmed: 18339857
doi: 10.1158/0008-5472.CAN-07-5092
Fults, D., Pedone, C., Dai, C. & Holland, E. C. MYC expression promotes the proliferation of neural progenitor cells in culture and in vivo. Neoplasia 4, 32–39 (2002).
pubmed: 11922389
pmcid: 1503312
doi: 10.1038/sj.neo.7900200
Jenkins, N. C. et al. Somatic cell transfer of c-Myc and Bcl-2 induces large-cell anaplastic medulloblastomas in mice. J. Neurooncol. 126, 415–424 (2016).
pubmed: 26518543
doi: 10.1007/s11060-015-1985-9
Dhar, S. S. et al. MLL4 is required to maintain broad H3K4me3 peaks and super-enhancers at tumor suppressor genes. Mol. Cell. 70, 825–841.e826 (2018).
pubmed: 29861161
pmcid: 6528658
doi: 10.1016/j.molcel.2018.04.028
Lee, C. et al. Lsd1 as a therapeutic target in Gfi1-activated medulloblastoma. Nat. Commun. 10, 332 (2019).
pubmed: 30659187
pmcid: 6338772
doi: 10.1038/s41467-018-08269-5
Han, Z. Y. et al. The occurrence of intracranial rhabdoid tumours in mice depends on temporal control of Smarcb1 inactivation. Nat. Commun. 7, 10421 (2016).
pubmed: 26818002
pmcid: 4738337
doi: 10.1038/ncomms10421
Ozawa, T. et al. A de novo mouse model of C11orf95-RELA fusion-driven ependymoma identifies driver functions in addition to NF-κB. Cell Rep. 23, 3787–3797 (2018).
pubmed: 29949764
pmcid: 6411037
doi: 10.1016/j.celrep.2018.04.099
Pajtler, K. W. et al. YAP1 subgroup supratentorial ependymoma requires TEAD and nuclear factor I-mediated transcriptional programmes for tumorigenesis. Nat. Commun. 10, 3914 (2019).
pubmed: 31477715
pmcid: 6718408
doi: 10.1038/s41467-019-11884-5
Eder, N. et al. YAP1/TAZ drives ependymoma-like tumour formation in mice. Nat. Commun. 11, 2380 (2020).
pubmed: 32404936
pmcid: 7220953
doi: 10.1038/s41467-020-16167-y